Zacks Investment Research downgraded shares of ZIOPHARM ONCLGY (ZIOP) from OUTPERFORM to NEUTRAL on July 09, 2014, with a target price of $3.80.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ZIOPHARM ONCLGY (ZIOP),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment